LINC02870: A Potential Drug Target and Biomarker (G170393)

Target Name: LINC02870

NCBI ID: G170393

LINC02870

Other Name(s): RP11-432J24.4 | Long intergenic non-protein coding RNA 2870 | BA432J24.4 | C10orf91 | long intergenic non-protein coding RNA 2870

LINC02870: A Potential Drug Target and Biomarker

LINC02870 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the myeloid-lymphoid transition, a critical step in the development and function of white blood cells. LINC02870 has been shown to play a role in the regulation of granulocyte development and function, as well as in the regulation of cellular processes such as cell adhesion and migration.

The Drug Target Potential

LINC02870 is a strong candidate for a drug target because of its unique structure and biology. It is a small non-coding RNA molecule that is expressed in a variety of tissues and cells, including the brain, spinal cord, and blood cells. It is highly conserved across species, which indicates that it has a conserved function. Additionally, LINC02870 has been shown to interact with a variety of protein molecules, including known drug targets such as tyrosine kinases and nuclear factor kappa B.

The Biomarker Potential

LINC02870 has also been shown to be a potential biomarker for a variety of diseases. For example, it has been shown to be downregulated in a variety of cancer types, including leukemia, and may be a potential therapeutic target for these diseases. Additionally, LINC02870 has been shown to be involved in the regulation of cellular processes that are relevant to a variety of diseases, including neurodegenerative diseases and autoimmune diseases.

The Potential therapeutic benefits of LINC02870 as a drug target and biomarker are significant. If it is successfully targeted by drugs, it has the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, because LINC02870 is a small molecule, it is relatively easy to synthesize and test, which could make it an attractive target for drug development.

Conclusion

In conclusion, LINC02870 is a promising drug target and biomarker. Its unique structure and biology, as well as its interaction with known drug targets, make it a strong candidate for targeting in cancer and other diseases. Further research is needed to determine its potential therapeutic benefits and to develop safe and effective drugs that can interact with LINC02870.

Protein Name: Long Intergenic Non-protein Coding RNA 2870

The "LINC02870 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02870 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets